Tiziana says KOL call ties Phase 2a foralumab data to years of expanded access results
Investigators said 12-week INFORM-MS findings in non-active secondary progressive MS align with longer-term benefits seen in patients treated for up to three years, Tiziana said November 9, 2026.
SEC filing (2)